Navigation Links
FDA Approves Xalkori with Companion Diagnostic for a Type of Late-stage Lung Cancer
Date:8/26/2011

SILVER SPRING, Md., Aug. 26, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Xalkori is being approved with a companion diagnostic test that will help determine if a patient has the abnormal ALK gene, a first-of-a-kind genetic test called the Vysis ALK Break Apart FISH Probe Kit. It is the second such targeted therapy approved by the FDA this year.

This ALK gene abnormality causes cancer development and growth. About 1 percent to 7 percent of those with NSCLC have the ALK gene abnormality. Patients with this form of lung cancer are typically non-smokers. Xalkori works by blocking certain proteins called kinases, including the protein produced by the abnormal ALK gene. Xalkori is a pill taken twice a day as a single-agent treatment.

"The approval of Xalkori with a specific test allows the selection of patients who are more likely to respond to the drug," said Richard Pazdur, M.D., director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "Targeted therapies such as Xalkori are important options for treating patients with this disease and may ultimately result in fewer side effects."

Xalkori's safety and effectiveness were established in two multi-center, single-arm studies enrolling a total of 255 patients with late-stage ALK-positive NSCLC. A sample of a patient's lung cancer tissue was collected and tested for the ALK gene abnormality prior to study enrollment. The studies were designed to measure objective response rate, the percentage of patients who experienced complete or partial cancer shrinkage. Most patients in the studies ha
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Firazyr To Treat Acute Attacks of Hereditary Angioedema
2. FDA Approves Adcetris to Treat Two Types of Lymphoma
3. FDA Approves the First Specific Treatment for Scorpion Stings
4. Cardinal Health Board of Directors Approves Cash Dividend, Elects David P. King as Director
5. FDA Tentatively Approves Intellijects Lead Product, e-cue™
6. FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in the US
7. FDA Approves Vaccines for the 2011-2012 Influenza Season
8. FDA Approves Boostrix to Prevent Tetanus, Diphtheria, and Pertussis in Older People
9. FDA Approves Arcapta Neohaler to Treat Chronic Obstructive Pulmonary Disease
10. FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery
11. FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  Today the U.S. Food and Drug ... the prevention of serogroup B meningococcal disease ... vaccine Trumenba®, which received FDA approval in October, represent ... disease. "I have heard over and ...
(Date:1/23/2015)... , Jan. 23, 2015 Research and Markets ... the "Urinary Catheters Market (Indwelling or Foley Catheters, ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... , At present, the global market for ...
(Date:1/23/2015)... Inc. (NASDAQ: NWBO )("NW Bio"), a U.S. biotechnology ... solid tumor cancers, announced today that CEO Linda Powers ... Immunotherapy Forum in Washington D.C. ... January 26 at 10:30 a.m. EST at the Grand Hyatt ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3
... NEW YORK, Nov. 16, 2011 Reportlinker.com ... is available in its catalogue: ... in Oncology http://www.reportlinker.com/p0379851/Analytical-Tool---Antibodies-and-Peptides-in-Oncology.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory ... and Peptides in Oncology" offers a unique ...
... FARMINGDALE, N.Y., Nov. 16, 2011 Misonix, Inc. ... company that designs, manufactures and markets innovative, therapeutic, ... cosmetic surgery, neurosurgery, laparoscopic surgery and other surgical ... exclusive distribution agreement with JPL Medical Co., Ltd. ...
Cached Medicine Technology:Analytical Tool - Antibodies and Peptides in Oncology 2Analytical Tool - Antibodies and Peptides in Oncology 3Misonix Announces New Distribution Agreement for Thailand 2Misonix Announces New Distribution Agreement for Thailand 3
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort ... as the number one best large hotel for families in ... for their annual Travelers’ Choice Awards. , TripAdvisor represents ... is home to millions of unbiased and honest traveler reviews. ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many ... it on Facebook, Twitter, and Pinterest. The fans will have ... a lottery every week. , Moreover, the company has extended ... Angelweddingdress homepage for more information. , Angelweddingdress ...
(Date:1/22/2015)... Dallas, TX (PRWEB) January 22, 2015 ... the issue of experience and person-centeredness in the long-term ... moving towards action across the continuum. The paper, “The ... the Continuum,” engages perspectives and practices of the patient, ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Joan Lunden, ... keynote speaker at the upcoming 32nd Annual Miami ... Physicians’ Education Resource®, LLC (PER®) , shares that ... have gone undetected if she had not followed up ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Four years since the ... – which coincided with the marriage of Avasa & Matthew Love ... ROAD, which is scheduled for release through White Swan Records on ... that there is a sacred path available to all of us ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... Jenesse Center Inc. for Complimentary Services and Fund ... LOS ANGELES, Oct. 15 Westside Medical Spa today,announced the ... the,confidence of women preparing to embark on a new chapter ... physical abuse, "Face the,Day" has partnered with Jenesse Center Inc., ...
... - Aspreva Pharmaceuticals,Corporation (NASDAQ: ASPV ; TSX: ... of evidence-based medicines available for patients,living with less ... financial and business results for the third quarter ... Aspreva will host a conference call to discuss ...
... Law Offers Safe Place for Unwanted Babies, Prevents Abandonment, ... Secretary Estelle B. Richman today reminded expectant,parents and parents ... confidentially turn over unwanted infants, up to 28 days ... On Oct. 10 in Sharon, Mercer County, a newborn ...
... in the November issue of the Journal of General Internal ... the Indiana University Center for Aging Research and the Regenstrief ... by most older adults, cannot meet the needs of the ... the primary care system approaches dementia. , ...
... on Role of Screening,Colonoscopy in Reducing Colorectal ... Today,s news from the,CDC and American Cancer ... in the United States includes heartening news ... the nation,s leading gastrointestinal,specialists are convening in ...
... Laurus Fully Repaid, LARGO, Fla., Oct. 15 ... ("Dynamic"), a leading distributor in,the sports nutrition product ... its Articles of Merger with the Florida Secretary ... its merger with GeoPharma, Inc.,(Nasdaq: GORX ) ...
Cached Medicine News:Health News:Westside Medical Spa Launches 'Face the Day' to Aid Battered Women 2Health News:Aspreva to Announce 2007 Third Quarter Results on October 31st 2Health News:PA Department of Public Welfare Reminds New Parents About 'Safe Haven' Law 2Health News:Editorial says primary care system must change how it approaches dementia 2Health News:Dynamic Files Articles of Merger; Notifies Nasdaq of Merger with GeoPharma 2Health News:Dynamic Files Articles of Merger; Notifies Nasdaq of Merger with GeoPharma 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: